Pharnext Strengthens its Management Team with Three Key Appointments to Support Ongoing Development of PXT3003 Toward Approval and Commercialization

Author's Avatar
Oct 19, 2021

PARIS, FRANCE / ACCESSWIRE / October 19, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY(TM) platform, is pleased to announce the strengthening of its senior management team with the appointments of Raj Thota, as Chief Manufacturing Officer and Head of CMC, Abhijit Pangu as the Head of Regulatory Affairs and the promotion of Xavier Paoli to Chief Operating Officer.